SCSaqib Chowdhary

Saqib Chowdhary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saqib Chowdhary has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher B. Overgaard

    Harold and Esther Mecklinger Family and the Posluns Family Cardiac Catheterization Research Laboratory, Mount Sinai Hospital, Toronto, ON, Canada (C.B.O., W.C., S.C., R.W., J.S.F.).

    1 shared publication
  • Christopher T. Chan

    Department of Medicine, University Health Network, Toronto, Ontario, Canada

    1 shared publication
  • David Hesketh Roberts

    School of Medicine, University of Liverpool, Liverpool L69 3GE, UK

    1 shared publication
  • Douglas G. Fraser

    Cardiology Department, Manchester Foundation Trust and Manchester University, Manchester Royal Infirmary, Manchester, United Kingdom

    1 shared publication
  • Izhar Hashmi

    Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK

    1 shared publication
  • John S. Floras

    University Health Network and Sinai Health Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada

    1 shared publication

Latest Publications

  • Coronary and Systemic Vasodilator Responsiveness of Patients Receiving Conventional Intermittent or Nocturnal Hemodialysis

    by Christopher B. Overgaard, William Chan, Saqib Chowdhary, Rebecca L. Zur, Rodrigo Wainstein, Vladimír Džavík, Christopher T. Chan, John S. Floras

    BACKGROUND: Nocturnal hemodialysis (nHD) restores the attenuated brachial artery vasodilator responsiveness of patients receiving conventional intermittent hemodialysis (iHD). Its impact on coronary vasodilatation is unknown. METHODS: We evaluated 25 patients on hemodialysis who fulfilled transplant criteria: 15 on iHD (4-hour sessions, 3 d/wk) and 10 on nHD (≈40 h/wk over 8–10-hour sessions) plus 6 control participants. Following diagnostic angiography, left anterior descending (LAD) coronary flow reserve and mean luminal diameter were quantified at baseline and during sequential intracoronary administration of adenosine (infusion and bolus), nitroglycerin (bolus), acetylcholine (infusion), acetylcholine coinfused with vitamin C, and, finally, sublingual nitroglycerin. RESULTS: Coronary flow reserve in those receiving nHD was augmented relative to iHD (3.28±0.26 versus 2.17±0.12 [mean±SEM]; P P =0.011). Luminal dilatations induced by intracoronary adenosine and nitroglycerin were similar in nHD and controls but blunted in the iHD cohort ( P P P <0.05, all comparisons). CONCLUSIONS: Coronary and systemic vasodilator responsiveness to both adenosine and nitroglycerin is augmented in patients receiving nHD relative to those receiving iHD, whereas vasoconstrictor responsiveness to acetylcholine does not differ. By improving coronary conduit and microvascular function, nHD may reduce the cardiovascular risk of patients on dialysis.


  • Open Access

    Does the CHA2DS2-Vasc score predict procedural and short-term outcomes in patients undergoing transcatheter aortic valve implantation?

    by Tahir Hamid, Tawfiq R Choudhury, Simon G Anderson, Izhar Hashmi, Saqib Chowdhary, David Hesketh Roberts, Douglas G Fraser, Ragheb Hasan, Vaikom S Mahadevan, Richard Levy

    Background: Transcatheter aortic valve implantation (TAVI) is associated with periprocedural and postprocedural morbidity and mortality. Currently, there is a paucity of risk stratification models for potential TAVI candidates. We employed the CHA2DS2-Vasc score to quantify the risk of 30-day mortality and morbidity in patients undergoing TAVI. Methods and results: A retrospective analysis of registry data for consecutive patients undergoing TAVI at 3 tertiary centres in Northwest England between 2008 and 2013. The CHA2DS2-Vasc score and its modification—the R2CHA2DS2-Vasc score, which includes pre-existing renal impairment and pre-existing conduction abnormality (right bundle branch block/left bundle branch block, RBBB/LBBB)—were calculated for all patients. A total of 313 patients with a mean age of 80 (79.1–80.8) years underwent TAVI. The implanted devices were either the CoreValve or the Edwards-SAPIEN prosthesis. The 30-day mortality was 14.3% in those with a CHA2DS2-Vasc score ≥6, whereas it was only 6.2% in those with a score 2-CHA2DS2-Vasc score, the difference was more pronounced with a 30-day mortality of 22.6% in those patients with an R2-CHA2DS2-Vasc score ≥7 compared to 6.0% in those with a R2-CHA2DS2-Vasc score 2DS2-Vasc score (hazard ratio (HR)= 2.71, (1.01 to 7.31); p2CHA2DS2-Vasc score (HR=4.27 (1.51 to 12.07); p=0.006) with 30-day mortality. Conclusions: Our study demonstrates the potential use of the CHA2DS2-Vasc or the R2CHA2DS2-Vasc score to quantify the risk of mortality in patients undergoing TAVI. This could have significant implications in terms of clinical as well as patients’ decision-making.